The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies : implications for the development of vaccines and antiviral agents
Based on a bioinformatics analysis of the Middle East respiratory syndrome coronavvirus (MERS-CoV) S protein, we synthesized a panel of peptides coupled to keyhole limpet haemocyanin and used them to raise antibodies in rabbits. In addition, the recombinant receptor-binding domain (RBD) was used to raise polyclonal antibodies in mice. All of the antibodies raised by S-peptide immunisation were specific and sensitive for S protein expressed in transfected cells in the indirect immunofluorescence assay or Western blotting. The RBD efficiently elicited neutralizing antibodies against MERS-CoV by blocking viral entry at the binding step. Furthermore, we found that the SP3 peptide, corresponding to amino-acid residues 736-761 of the S protein, elicited robust neutralizing activities by blocking viral entry at the postbinding and membrane fusion steps. We conclude that amino-acid residues 736-761 of the S protein carry neutralizing epitopes that may be used in the development of vaccines and antiviral agents against MERS-CoV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Viral immunology - 27(2014), 10 vom: 04. Dez., Seite 543-50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 23.07.2015 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1089/vim.2014.0080 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM243450346 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM243450346 | ||
| 003 | DE-627 | ||
| 005 | 20231224132545.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/vim.2014.0080 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0811.xml |
| 035 | |a (DE-627)NLM243450346 | ||
| 035 | |a (NLM)25387086 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Yang |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies |b implications for the development of vaccines and antiviral agents |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2015 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Based on a bioinformatics analysis of the Middle East respiratory syndrome coronavvirus (MERS-CoV) S protein, we synthesized a panel of peptides coupled to keyhole limpet haemocyanin and used them to raise antibodies in rabbits. In addition, the recombinant receptor-binding domain (RBD) was used to raise polyclonal antibodies in mice. All of the antibodies raised by S-peptide immunisation were specific and sensitive for S protein expressed in transfected cells in the indirect immunofluorescence assay or Western blotting. The RBD efficiently elicited neutralizing antibodies against MERS-CoV by blocking viral entry at the binding step. Furthermore, we found that the SP3 peptide, corresponding to amino-acid residues 736-761 of the S protein, elicited robust neutralizing activities by blocking viral entry at the postbinding and membrane fusion steps. We conclude that amino-acid residues 736-761 of the S protein carry neutralizing epitopes that may be used in the development of vaccines and antiviral agents against MERS-CoV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Deng, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Huijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Jiaming |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, George F |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Wenjie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viral immunology |d 1993 |g 27(2014), 10 vom: 04. Dez., Seite 543-50 |w (DE-627)NLM012623369 |x 1557-8976 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2014 |g number:10 |g day:04 |g month:12 |g pages:543-50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/vim.2014.0080 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2014 |e 10 |b 04 |c 12 |h 543-50 | ||